Defining the Molecular Evolution of Extrauterine High Grade Serous Carcinoma
Overview
Authors
Affiliations
Objective: High grade serous carcinoma (HGSC) is the most common and most aggressive, subtype of epithelial ovarian cancer. It presents as advanced stage disease with poor prognosis. Recent pathological evidence strongly suggests HGSC arises from the fallopian tube via the precursor lesion; serous tubal intraepithelial carcinoma (STIC). However, further definition of the molecular evolution of HGSC has major implications for both clinical management and research. This study aims to more clearly define the molecular pathogenesis of HGSC.
Methods: Six cases of HGSC were identified at the Northern Ireland Gynaecological Cancer Centre (NIGCC) that each contained ovarian HGSC (HGSC), omental HGSC (OMT), STIC, normal fallopian tube epithelium (FTE) and normal ovarian surface epithelium (OSE). The relevant formalin-fixed paraffin embedded (FFPE) tissue samples were retrieved from the pathology archive via the Northern Ireland Biobank following attaining ethical approval (NIB11:005). Full microarray-based gene expression profiling was performed on the cohort. The resulting data was analysed bioinformatically and the results were validated in a HGSC-specific in-vitro model.
Results: The carcinogenesis of HGSC was investigated and showed the molecular profile of HGSC to be more closely related to normal FTE than OSE. STIC lesions also clustered closely with HGSC, indicating a common molecular origin.
Conclusion: This study provides strong evidence suggesting that extrauterine HGSC arises from the fimbria of the distal fallopian tube. Furthermore, several potential pathways were identified which could be targeted by novel therapies for HGSC. These findings have significant translational relevance for both primary prevention and clinical management of the disease.
Biomarkers in Ovarian Cancer: Towards Personalized Medicine.
Lopez-Portugues C, Montes-Bayon M, Diez P Proteomes. 2024; 12(1).
PMID: 38535506 PMC: 10974094. DOI: 10.3390/proteomes12010008.
Zeng J, Alvarez-Yela A, Casarez E, Jiang Y, Wang L, Kelly B iScience. 2023; 26(5):106742.
PMID: 37207276 PMC: 10189502. DOI: 10.1016/j.isci.2023.106742.
Nucleic acid vaccination strategies for ovarian cancer.
Saha C, Bojdo J, Dunne N, Duary R, Buckley N, McCarthy H Front Bioeng Biotechnol. 2022; 10:953887.
PMID: 36420446 PMC: 9677957. DOI: 10.3389/fbioe.2022.953887.
PAX8 as a Potential Target for Ovarian Cancer: What We Know so Far.
Di Palma T, Zannini M Onco Targets Ther. 2022; 15:1273-1280.
PMID: 36275185 PMC: 9584354. DOI: 10.2147/OTT.S361511.
A bespoke target selection tool to guide biomarker discovery in tubo-ovarian cancer.
Beirne J, Gilmore A, McInerney C, Roddy A, McCluggage W, Harley I Comput Struct Biotechnol J. 2022; 20:3359-3371.
PMID: 35832628 PMC: 9260242. DOI: 10.1016/j.csbj.2022.06.016.